Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04104438 · ClinicalTrials.gov registry record · Phase 4
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
A Phase 4 study of Asses Immunosuppression Modulation on Renal Recovery Post LT, sponsored by Fady M Kaldas, M.D., F.A.C.S..
- Completed
- Registry status
- Phase 4
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT04104438 is a Phase 4 study of Asses Immunosuppression Modulation on Renal Recovery Post LT that has completed, run by Fady M Kaldas, M.D., F.A.C.S.. The registered enrollment target is 71 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04104438, a Phase 4 study of Asses Immunosuppression Modulation on Renal Recovery Post LT, has completed, sponsored by Fady M Kaldas, M.D., F.A.C.S..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard immunosuppressive medications after your liver transplant. Also the study will assess how safe the new combination of immunosuppressive medicines are and if there are any changes in how your kidneys work after taking these medicines.
Conditions Studied
Interventions
- DRUG Basiliximab 20 MG
Study Locations (1)
California
- UCLA Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04104438
The ClinicalTrials.gov registry entry for NCT04104438 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fady M Kaldas, M.D., F.A.C.S., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asses Immunosuppression Modulation on Renal Recovery Post LT appearing as the primary indexed condition, and to 1 intervention - of which Basiliximab 20 MG is the first listed.
NCT04104438 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04104438 about?
NCT04104438 is a clinical study titled "Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant". This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard immunosuppressive medications after your liver transplant. Also the study wi...
What is the current status of trial NCT04104438?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 71 participants. The study started on 2021-01-15. Estimated completion is 2024-09-30.
What conditions does trial NCT04104438 study?
This clinical trial studies the following conditions: Asses Immunosuppression Modulation on Renal Recovery Post LT.
What interventions are being tested in trial NCT04104438?
The interventions under investigation include: Basiliximab 20 MG (DRUG).
Who is sponsoring clinical trial NCT04104438?
This trial is sponsored by Fady M Kaldas, M.D., F.A.C.S., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04104438 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.